Lipocine Inc. (NASDAQ:LPCN) Stock Short Interest Report for October

Lipocine Inc. (NASDAQ:LPCN) saw a large increase in short interest in October. As of October 15th, there was short interest totaling 351,433 shares, an increase of 259.3% from the September 30th total of 97,816 shares. Approximately 4.5% of the company’s stock are sold short. Based on an average daily trading volume, of 9,616,895 shares, the days-to-cover ratio is currently 0.0 days.

Insider Transactions at Lipocine

In other Lipocine news, Director John Higuchi purchased 15,970 shares of the firm’s stock in a transaction on Wednesday, September 30th. The stock was bought at an average price of $2.23 per share, with a total value of $35,613.10. Following the transaction, the director directly owned 241,365 shares of the company’s stock, valued at approximately $538,243.95. This represents a 7.09% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have purchased 37,568 shares of company stock worth $82,174. 4.69% of the stock is owned by corporate insiders.

Institutional Trading of Lipocine

A number of institutional investors have recently bought and sold shares of LPCN. Dimensional Fund Advisors LP lifted its stake in Lipocine by 57.5% during the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in Lipocine in the first quarter valued at approximately $185,000. Exome Asset Management LLC acquired a new position in Lipocine in the first quarter valued at approximately $486,000. Seven Fleet Capital Management LP purchased a new position in Lipocine in the first quarter valued at approximately $998,000. Finally, Stempoint Capital LP purchased a new position in Lipocine in the first quarter valued at approximately $1,282,000. 9.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Weiss Ratings lowered Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 9th. HC Wainwright reiterated a “neutral” rating and issued a $4.00 target price on shares of Lipocine in a report on Monday, September 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Lipocine in a research note on Tuesday, September 22nd. Finally, Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Lipocine currently has an average rating of “Hold” and an average target price of $4.00.

Lipocine Stock Up 0.7%

NASDAQ LPCN traded up $0.01 on Thursday, hitting $1.52. 139,014 shares of the stock were exchanged, compared to its average volume of 715,067. Lipocine has a fifty-two week low of $1.40 and a fifty-two week high of $12.37. The company has a 50-day moving average price of $2.01 and a 200-day moving average price of $4.07. The company has a market cap of $12.53 million, a PE ratio of -0.85 and a beta of 0.40.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. As a group, equities research analysts predict that Lipocine will post -1.54 EPS for the current fiscal year.

Lipocine Company Profile

Lipocine Inc is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.

Lipocine’s lead product is Tlando, an oral testosterone replacement therapy containing testosterone undecanoate. The U.S. Food and Drug Administration approved Tlando in 2022 for testosterone replacement therapy in adult males with hypogonadism associated with an underlying medical condition.